#3494
Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumors
Introduction:
Lutetium Peptide Receptor Radio Nuclide Therapy (Lu-PRRT) is an effective treatment for progressive, metastatic, somatostatin-receptor-positive, well-differentiated Neuroendocrine Tumors (WD-NETs). It is generally well tolerated.
Conference:
Presenting Author:
Authors:
Almeamar H,
Cullen L,
Murphy D,
Crowley R,
Skehan S,
Keywords:
prrt,
neuroendocrine tumor,
efficacy,
safety,
#2168
Phase II Trial of Cabozantinib in Patients with Carcinoid and Pancreatic Neuroendocrine Tumors
Introduction:
Activation of VEGFR2 and MET is implicated in driving growth of NET. Cabozantinib inhibits VEGFR2, MET, AXL, RET.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Authors:
Chan J,
Faris J,
Murphy J,
Blaszkowsky L,
McCleary N,
Keywords:
cabozantinib,
pancreatic neuroendocrine tumor,
carcinoid,
phase II,
#294
Chromogranin B is a Prognostic Marker in NETs
Introduction:
Chromogranin B (CgB) co-localizes with Chromogranin A (CgA) in the secretory granules of neuroendocrine cells. Previous studies have investigated CgA, but not CgB, as a prognostic marker in NETs.
Conference:
8th Annual ENETSConcerence (2011)
Presenting Author:
Authors:
Bech P,
Ramachandran R,
Martin N,
Murphy K,
Dhillo W,
Keywords:
Chromogranin A,
Chromogranin B,
prognosis,
neuroendocrine tumor,
midgut,
#267
Plasma Somatostatin: Gastrin Ratio Improves the Diagnosis of Gastrinoma
Introduction:
Fasting gastrin alone is inadequate for diagnosis of gastrinoma. Diagnosis requires confirmation of low gastric pH. Low gastric pH is associated with increased numbers of D (somatostatin) cells.
Conference:
8th Annual ENETSConcerence (2011)
Presenting Author:
Authors:
Ramachandran R,
Bech P,
Murphy K,
Dhillo W,
Marelli L,
Keywords:
somatostatin,
gastrin,
ratio,
gastrinoma,
gastric pH,
Cg A,
atrophic gastritis
,
